Friday, 19 April 2024
  
Login

Australia's most trusted
source of pharma news

Friday, 19 April 2024
Listen to this story 
News

GSK plays hardball in sell-off

Posted 19 January 2022 PM

GSK says it has received, and rejected, three unsolicited bids for its GSK Consumer Healthcare joint venture with Pfizer, which it plans to spin-off in the middle of this year.

The three bids have come from Unilever, with the latest offer being 50 billion pounds (AUD$95 billion), with 41.7 billion pounds in cash and the rest in Unilever shares.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (22)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (7)

Devices (1)

Other (25)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.